Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ) has shared an update.
Shanghai Haohai Biological Technology Co., Ltd. has proposed a final ordinary cash dividend of RMB 0.6 per share for the financial year ended 31 December 2025, subject to shareholders’ approval. The dividend will be paid in Hong Kong dollars for H-share investors, with the exact HKD amount, exchange rate, key dates for ex-dividend, book closure, record and payment, as well as applicable withholding tax arrangements, to be announced in due course.
The announcement underscores the company’s intention to return cash to shareholders following its 2025 annual results, signalling confidence in its financial performance and cash-generating capacity. However, investors will need to await further details on timing, currency conversion and tax treatment, which may affect the ultimate yield for different shareholder groups and could influence trading around the ex-dividend period.
The most recent analyst rating on (HK:6826) stock is a Buy with a HK$28.00 price target. To see the full list of analyst forecasts on Shanghai Haohai Biological Technology Co., Ltd. Class H stock, see the HK:6826 Stock Forecast page.
More about Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd., listed in Hong Kong under stock code 06826, operates in the biomedical sector, focusing on biological technologies and related medical products. The company issues ordinary shares, including a class H listing in Hong Kong, and is overseen by a board comprising executive, non-executive and independent non-executive directors.
Average Trading Volume: 141,921
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$10.01B
See more insights into 6826 stock on TipRanks’ Stock Analysis page.